Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development
Reference number: GID-TA11284
Expected publication date: TBC
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.